A two-year double-blind crossover trial of the prophylactic effect of methylene blue in manic-depressive psychosis (1986)

Peer-Reviewed Study · Naylor GJ, Martin B, Hopwood SE, Watson Y. · August 1986

Naylor GJ et al., 1986-08: Two-year double-blind crossover prophylaxis trial in 31 bipolar patients on lithium, comparing 300 mg/day with 15 mg/day methylene blue; 17 completed, and depression was significantly lower on 300 mg/day with no difference in mania.

The trial had obvious limitations, e.g., a small number of subjects, a relatively large number of dropouts, relatively simple rating scales, doubts about blindness, and uncertainty as to whether or not 15 mg methylene blue per day could be considered a placebo.

Naylor GJ et al., 1986-08: Two-year double-blind crossover prophylaxis trial in 31 bipolar patients on lithium, comparing 300 mg/day with 15 mg/day methylene blue; 17 completed, and depression was significantly lower on 300 mg/day with no difference in mania. Study type: double-blind crossover prophylaxis trial (randomisation procedure not stated in the abstract). N=31 enrolled, 17 completed the 2-year trial. Country: UK (Dundee). Dose: 300 mg/day oral vs 15 mg/day oral, each for one year, all patients maintained on lithium. Comparator: low-dose methylene blue (15 mg/day) used as an intended placebo, not true placebo. Funder and conflicts not stated in abstract. Authors' stated limitations quoted: small number of subjects, large number of dropouts, simple rating scales, doubts about blindness, uncertainty whether 15 mg/day is a placebo. Also filed as MTK-28, MTC-071, MTF-06 (claims C1, C11, C5, C7). Study type: controlled study.